Regions4PerMed Workshops on Personalising Health Industry

8 April 2021 – The ICPerMed-related CSA Regions4PerMed organizes two workshops on Personalising Health Industry. The first workshop “A Regional R&D Ecosystem for Personalising Health Industry – Spotlight on the Free State of Saxony” will take place on 28 April 2021 and the second workshop “Regional Translational Ecosystems Supportive of Personalising Health Industry” will take place on 19 May 2021.

The 1st workshop goes by the title of “A Regional R&D Ecosystem for Personalising Health Industry – Spotlight on the Free State of Saxony” and will take place on April 28th 2021, 1-4 p.m.: “It is well recognised that a thriving R&D ecosystem is a facilitator and an important resource for innovation in almost any scientific field. The concept of R&D innovation ecosystem implies that academic R&D-related innovation potential feeds into industry and vice versa. Relations are manifold, with proximity and closer social contacts between actors and supporting structures such as tech transfer and cluster organisations serving as catalysers. These ecosystems may enhance industry development by providing essential R&D infrastructures for personalised medicine and health, as much as by generating qualified human resources. A well-functioning regional R&D ecosystem may offer high-tech services on one hand, and on the other guidance by generating role models for entrepreneurship and the translation of scientific breakthroughs into tangible innovative products.”

To find out more and register please go here.
 
The 2nd workshop goes by the title “Regional Translational Ecosystems Supportive of Personalising Health Industry” and will take place on 19 May 2021, 1-4 pm: “Bringing innovation from the R&D phase to the market requires translational and frequently also entrepreneurial efforts. However, to realize these has long been identified as a bottle-neck resulting in a valley of death for many projects. To pass this gap, it has been proposed and discussed, to reduce the risk profile of new ventures and translational activities by providing comprehensive early-stage support schemes and structures. De-risking is also seen as an important strategy to counteract against the lack of risk capital availability throughout Europe. Though this idea is not entirely novel, as first business incubators for the life sciences were already set up in the late 90s in Europe, the concepts have been developed further and become more refined, and relevant expertise has grown as structures have institutionalised and professionalised.”

To find out more and register please go here.